

DAFTAR PUSTAKA

- Arciero, C. A. *et al.* (2019) 'Original Study ER⁺ / HER2⁻ Breast Cancer Has Different Metastatic Patterns and Better Survival Than', *Clinical Breast Cancer*, 19(4), pp. 236–245. doi: 10.1016/j.clbc.2019.02.001.
- Bray, F. *et al.* (2018) 'Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries', *CA: A Cancer Journal for Clinicians*, 68(6), pp. 394–424. doi: 10.3322/caac.21492.
- Cancer, T. and Atlas, G. (2012) 'Comprehensive molecular portraits of human breast tumours', pp. 1–10. doi: 10.1038/nature11412.
- Chia, S. *et al.* (2008) 'JOURNAL OF CLINICAL ONCOLOGY Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers', 26(35). doi: 10.1200/JCO.2007.15.8659.
- Comen, E., Norton, L. and Massagué, J. (2011) 'Clinical implications of cancer self-seeding', *Nature reviews. Clinical oncology*, 8(6), pp. 369–377. doi: 10.1038/NRCLINONC.2011.64.
- Conlin, A. K. *et al.* (2018) 'Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer', pp. 1–12. doi: 10.1056/NEJMoa1814017.
- Dieci, M. V. *et al.* (2014) 'Rare Breast Cancer Subtypes: Histological, Molecular, and Clinical Peculiarities', *The Oncologist*, 19(8), p. 805. doi: 10.1634/THEONCOLOGIST.2014-0108.
- Ekpe, E. *et al.* (2019) 'Metastatic Breast Cancer in Kenya : Presentation , Pathologic Characteristics , and Patterns — Findings From a Tertiary Cancer Center original report abstract', pp. 14–16. doi: 10.1200/JGO.19.00036.
- Erić, I. *et al.* (2018) 'Breast cancer in young women: Pathologic and immunohistochemical features', *Acta Clinica Croatica*, 57(3), pp. 497–502. doi: 10.20471/acc.2018.57.03.13.
- Falck, A. *et al.* (2013) 'St Gallen molecular subtypes in primary breast cancer and matched lymph node metastases - aspects on distribution and prognosis for patients with luminal A tumours : results from a prospective randomised trial', pp. 1–10.
- Fechner, R. E. (1995) 'Recommendations for the reporting of breast carcinoma', *American Journal of Clinical Pathology*, 104(6), pp. 614–619. doi: 10.1093/AJCP/104.6.614.
- Ferlay, J. *et al.* (2015) 'Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012', *International Journal of Cancer*, 136(5), pp. E359–E386. doi: 10.1002/IJC.29210.
- Feys, L. *et al.* (2015) 'Radiation-induced lung damage promotes breast cancer lung-metastasis through CXCR4 signaling', *Oncotarget*, 6(29), pp. 26615–26632. doi: 10.18632/oncotarget.5666.
- Gerratana, L. *et al.* (2015) 'Pattern of metastasis and outcome in patients with breast cancer', *Clinical and Experimental Metastasis*, 32(2), pp. 125–133. doi: 10.1007/s10585-015-9697-2.
- Goldhirsch, A. *et al.* (2011) 'Strategies for subtypes — dealing with the diversity of breast cancer : highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011', (June), pp. 1736–1747. doi:

- 10.1093/annonc/mdr304.
- Goldhirsch, A. *et al.* (2013) ‘Personalizing the treatment of women with early breast cancer : highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013’, pp. 2206–2223. doi: 10.1093/annonc/mdt303.
- Hanby, A. M. and Walker, C. (2004) ‘Book report The WHO , and what of the breast and female genital organs : part IV in the WHO classification of tumours series’, pp. 133–134. doi: 10.1186/bcr788.
- Howlader, N. *et al.* (2018) ‘Differences in Breast Cancer Survival by Molecular Subtypes in the United States’, 27, 6, pp. 619–626. doi: 10.1158/1055-9965.EPI-17-0627.
- Howlader N.N.A. *et al.* (2017) *SEER Cancer Statistics Review, 1975–2017, National Cancer Institute.*
- Iqbal, Nida and Iqbal, Naveed (2014) ‘Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications’, *Molecular Biology International*, 2014, pp. 1–9. doi: 10.1155/2014/852748.
- Jin, L. *et al.* (2018) ‘Breast cancer lung metastasis: Molecular biology and therapeutic implications’, *Cancer Biology & Therapy*, 19(10), p. 858. doi: 10.1080/15384047.2018.1456599.
- Karlsson, E. *et al.* (2014) ‘Breast cancer during follow-up and progression - A population based cohort on new cancers and changed biology’, *European Journal of Cancer*, 50(17), pp. 2916–2924. doi: 10.1016/j.ejca.2014.08.014.
- Kedrin, D. *et al.* (2009) ‘ERBB1 and ERBB2 have distinct functions in tumor cell invasion and intravasation’, *Clinical cancer research : an official journal of the American Association for Cancer Research*, 15(11), p. 3733. doi: 10.1158/1078-0432.CCR-08-2163.
- Kennecke, H. *et al.* (2010) ‘JOURNAL OF CLINICAL ONCOLOGY Metastatic Behavior of Breast Cancer Subtypes’, 28(20), pp. 3271–3277. doi: 10.1200/JCO.2009.25.9820.
- Keshtgar, M. *et al.* (2010) ‘Current status and advances in management of early breast cancer’, *International Journal of Surgery*, 8(3), pp. 199–202. doi: 10.1016/J.IJSU.2010.02.004.
- Kim, Y. J. *et al.* (2018) ‘Molecular subtype predicts incidence and prognosis of brain metastasis from breast cancer in SEER database’, *Journal of Cancer Research and Clinical Oncology*, 0(0), p. 0. doi: 10.1007/s00432-018-2697-2.
- Lacroix, M. (2006) ‘Significance , detection and markers of disseminated breast cancer cells’, pp. 1033–1067. doi: 10.1677/ERC-06-0001.
- Leong, S. P. L. *et al.* (2010) ‘Is Breast cancer the same disease in Asian and Western countries?’, *World Journal of Surgery*, 34(10), pp. 2308–2324. doi: 10.1007/s00268-010-0683-1.
- Lester, S. C. *et al.* (2009) ‘Protocol for the Examination of Specimens From Patients With Ductal Carcinoma In Situ of the Breast’, *Archives of Pathology & Laboratory Medicine*, 133(1), pp. 15–25. doi: 10.5858/133.1.15.
- Li, C. I., Uribe, D. J. and Daling, J. R. (2005) ‘Clinical characteristics of different histologic types of breast cancer’, *British Journal of Cancer*, 93(9), p. 1046. doi: 10.1038/SJ.BJC.6602787.
- Liang, Y. *et al.* (2019) ‘Seminars in Cancer Biology Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets’,

- Seminars in Cancer Biology*, (April), pp. 0–1. doi: 10.1016/j.semcancer.2019.08.012.
- Liu, Y. and Xu, L. (2010) ‘The current status in diagnosis and treatment of breast cancer’, *Chinese Journal of Surgery*, 48(24), pp. 1841–6.
- Ma, R. *et al.* (2015) ‘Mechanisms involved in breast cancer liver metastasis’, *Journal of Translational Medicine*, 13(1). doi: 10.1186/S12967-015-0425-0.
- Malhotra, G. K. *et al.* (2010) ‘Histological, molecular and functional subtypes of breast cancers’, pp. 955–960. doi: 10.4161/cbt.10.10.13879.
- Minn, A. J. *et al.* (2005) ‘Genes that mediate breast cancer metastasis to lung’, *Nature*, 436(7050), p. 518. doi: 10.1038/NATURE03799.
- Monteran, L. *et al.* (2020) ‘Bone metastasis is associated with acquisition of mesenchymal phenotype and immune suppression in a model of spontaneous breast cancer metastasis’, *Scientific Reports*, (0123456789), pp. 1–14. doi: 10.1038/s41598-020-70788-3.
- Mueller, C. *et al.* (2019) ‘HHS Public Access’, 15(2), pp. 131–152. doi: 10.1080/14789450.2018.1421071.Protein.
- Reis-filho, J. S. and Ph, D. (2010) ‘Triple-Negative Breast Cancer’, 363, 20, pp. 1038–48.
- Riggio, A. I., Varley, K. E. and Welm, A. L. (2021) ‘The lingering mysteries of metastatic recurrence in breast cancer’, *British Journal of Cancer*, (November 2020). doi: 10.1038/s41416-020-01161-4.
- Ristimäki, A., Sivula, A. and Lundin, J. (2002) ‘Prognostic Significance of Elevated Cyclooxygenase-2 Expression in Breast Cancer’, (February).
- Rojas, K. and Stuckey, A. (2016) ‘Breast Cancer Epidemiology and Risk Factors’, *Clinical Obstetrics and Gynecology*, 59(4), pp. 651–672. doi: 10.1097/GRF.0000000000000239.
- Rostami, R. *et al.* (2016) ‘Brain metastasis in breast cancer: a comprehensive literature review’, *Journal of Neuro-Oncology*, 127(3), pp. 407–414. doi: 10.1007/s11060-016-2075-3.
- Schnitt, S. J. (2010) ‘Classification and prognosis of invasive breast cancer: From morphology to molecular taxonomy’, *Modern Pathology*, 23, pp. 60–64. doi: 10.1038/MODPATHOL.2010.33.
- Scully, O. J. *et al.* (2012) ‘Breast Cancer Metastasis’, 320, pp. 311–320.
- Siegel, R. L., Miller, K. D. and Jemal, A. (2019) ‘Cancer statistics, 2019’, *CA: A Cancer Journal for Clinicians*, 69(1), pp. 7–34. doi: 10.3322/CAAC.21551.
- Sihto, H. *et al.* (2011) ‘Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study’, *Breast Cancer Research: BCR*, 13(5), p. R87. doi: 10.1186/BCR2944.
- Tabor, S. *et al.* (2020) ‘How to Predict Metastasis in Luminal Breast Cancer? Current Solutions and Future Prospects’, *International Journal of Molecular Sciences*, 21(21), pp. 1–21. doi: 10.3390/IJMS21218415.
- Tulotta, C. and Ottewill, P. (2018) ‘The role of IL-1B in breast cancer bone metastasis’, *Endocrine-Related Cancer*, 25(7), pp. R421–R434. doi: 10.1530/ERC-17-0309.
- Weigelt, B., Peterse, J. L. and Veer, L. J. Van (2005) ‘REVIEWS BREAST CANCER METASTASIS’, 5(August), pp. 591–602. doi: 10.1038/nrc1670.
- Winters, S. *et al.* (2017) ‘Breast Cancer Epidemiology, Prevention, and Screening’, *Progress in Molecular Biology and Translational Science*, 151, pp. 1–32. doi:

10.1016/BS.PMBTS.2017.07.002.

Wu, Q. *et al.* (2017) 'Breast cancer subtypes predict the preferential site of distant metastases : a SEER based study', 8(17), pp. 27990–27996.

Wu, S. *et al.* (2016) 'Patterns of distant metastasis in Chinese women according to breast cancer subtypes', 7(30).

Xiao, W. *et al.* (2018) 'Cancer Medicine'. doi: 10.1002/cam4.1370.

Yang, Y. S. X. and Zhou, J. (2011) 'Circulating tumor cells : advances in detection methods , biological issues , and clinical relevance', pp. 1151–1173. doi: 10.1007/s00432-011-0988-y.

Yin, L. *et al.* (2020) 'Triple-negative breast cancer molecular subtyping and treatment progress', pp. 1–13.

LAMPIRAN

LAMPIRAN 1

CURRICULUM VITAE



Data Pribadi:

Nama : Ahmad Abizart
Nama Panggilan : Abizart
NIM : C011191105
Tempat, Tanggal lahir : Pangkep, 17 Juli 2000
Pekerjaan : Mahasiswa
Jenis Kelamin : Laki-laki
Agama : Islam
Golongan Darah : O
Jurusan/Fakultas : Pendidikan Dokter/Kedokteran
Alamat : Jl. Perintis Kemerdekaan IX, Makassar
No. telp : 085156430497
Email : abizart.17@gmail.com

Riwayat Pendidikan:

No.	Institusi dan Bidang Ilmu/Jurusan	Periode
1.	TK Pertiwi Kecamatan Bungoro	2005 – 2006
2.	SDN 2 Lejang	2006 – 2012
3.	SMPN 1 Bungoro	2012 – 2015
4.	SMAN 11 Pangkep/MIPA	2015 – 2018
5.	Universitas Hasanuddin/Fakultas Kedokteran	2019 – Sekarang

LAMPIRAN 2

**DATA SAMPEL PASIEN KANKER PAYUDARA STADIUM AKHIR DI
RUMAH SAKIT UMUM PUSAT WAHIDIN SUDIROHUSODO PADA
PERIODE JANUARI 2020 – APRIL 2022**

No. RM	Umur	IHC	Subtipe	Metastasis	Histopatologi
937083	41			Paru	<i>Invasive breast carcinoma of no special type grade 2</i>
746224	60			otak	<i>Invasive ductal carcinoma mammae high grade</i>
771903	50	ER(+) PR(-) Her 2 (+)	<i>Luminal B</i>	Tulang	<i>Invasive ductal carcinoma mammae high grade</i>
952652	44			Hepar, paru	
412869	41			Paru, tulang (vertebra)	
915387	58			Paru	<i>Invasive carcinoma of no special type (NST)</i>
906761	52			paru, tulang (vertebra)	<i>Invasive carcinoma of no special type (NST)</i>
205581	68	ER(+) PR(-) Her 2(-)	Luminal B	KGB axilla	<i>Invasive carcinoma of no special type (NST)</i>
899481	51			Tulang (vertebra, costae, pelvis)	<i>Invasive ductal carcinoma mammae</i>
909382	57	ER(+) PR(+) Her 2(-)	Luminal A	Tulang	<i>Invasive carcinoma of no special type (NST)</i>
878911	59	ER(+) PR(+) HER 2(-)	Luminal A	Hepar	<i>Invasive carcinoma of no special type (NST)</i>
771903	50	ER(+) PR(-) Her 2(+)	<i>Luminal B</i>	Tulang	<i>Invasive ductal carcinoma</i>

					<i>mammae high grade</i>
891913	51			Pleura, hepar	<i>Invasive carcinoma mammae of no special type</i>
691343	55	ER(+) PR(+) Her 2(-)	Luminal A	Tulang, paru	<i>Invasive carcinoma of no special type (NST)</i>
690535	61			KGB supraclavicula	<i>Invasive ductal carcinoma mammae low grade</i>
915636	51			Paru	<i>Invasive lobular carcinoma mamma</i>
427566	56			Tulang	<i>Invasive carcinoma of no special type moderate grade</i>
267386	63	ER(+) PR(+) Her 2(-)	Luminal A	Tulang	<i>Invasive carcinoma of no special type low grade</i>
951365	65	ER(+) PR(+) Her 2(+)	<i>Luminal B</i>	Hepar	<i>Invasive micropapillary carcinoma mamma</i>
776314	52	ER(+) PR(+) Her 2(-)	Luminal A	Tulang	<i>Invasive ductal carcinoma mammae, low grade</i>
857414	43			Tulang	<i>Invasive lobular carcinoma mamma</i>
899794	68	ER(+) PR(+) Her 2(+)	<i>Luminal B</i>	Pleura	<i>Invasive carcinoma mammae of no special type, moderate grade</i>
864542	49	ER(-) PR(-) Her 2(+)	<i>HER2 Overexpression</i>	Otak	<i>Invasive carcinoma mammae of no special type, moderate grade</i>

854532	35			Paru	<i>Adenocarcinoma mucinosum low grade</i>
872944	63	ER(-) PR(-) Her 2(-)	<i>Triple negative</i>	Paru, hepar	<i>Invasive ductal carcinoma mamma, moderate grade</i>
911644	35	ER(+) PR(-) Her 2(-)	Luminal B	Paru	<i>Invasive carcinoma mammae of no special type, modarately differentiated</i>
796864	38	ER(+) PR(+) Her 2(-)	Luminal A	Tulang	<i>Invasive carcinoma mamae of no special type, grade II</i>
906594	55			Tulang (vertebra, costae)	<i>Invasive ductal carcinoma mamma, moderate grade</i>
893177	50			Hepar	<i>Invasive carcinoma mammae of no special type, moderate differentiated</i>
842557	52	ER(-) PR(-) Her 2(+)	<i>HER2 Overexpression</i>	Paru, tulang	<i>Invasive carcinoma mammae of no special type, high grade malignancy</i>
767517	49	ER(+) PR(+) Her 2(-)	Luminal A	Pleura, tulang (costae)	<i>Invasive carcinoma mammae of no special type, moderate grade malignancy</i>
897057	44	ER(-) PR(-) Her 2(-)	<i>Triple negative</i>	Pleura, tulang (costae)	<i>Invasive carcinoma mammae of no special type, high grade malignancy</i>
912257	51	ER(-) PR(-) Her 2(+)	<i>HER2 Overexpression</i>	Paru	<i>Invasive carcinoma</i>

					<i>mammae of no special type, grade 3</i>
911037	50			Paru, hepar	<i>Invasive carcinoma mammae of no special type, grade 3</i>
588907	52			Tulang (vertebra)	<i>Invasive carcinoma mammae of no special type, grade 3</i>
906987	56			Paru, tulang	
792387	56			Paru	<i>Invasive carcinoma mammae of no special type, moderate grade</i>
854897	44	ER(-) PR(-) Her 2 (+)	<i>HER2 Overexpression</i>	Tulang (vertebra)	<i>Invasive carcinoma mammae of no special type, low grade malignancy</i>
925611	51	ER(+) PR(+) Her 2(+)	<i>Luminal B</i>	Tulang (vertebra, femur Dex), paru	<i>Invasive carcinoma mammae of no special type, moderately differentiated</i>
791060	48			Tulang (vertebra)	<i>Invasive ductal carcinoma mammae of no special type, moderate grade malignancy</i>
929911	40	ER(-) PR(+) Her 2(-)	Luminal A	Tulang (vertebra)	<i>Invasive carcinoma mammae of no special type, moderate grade malignancy</i>
838701	47	ER (+) PR(+) Her 2(+)	<i>Luminal B</i>	Tulang (vertebra)	<i>Invasive carcinoma mammae of no special type, moderate grade</i>

942690	50			Tulang	
937720	42			Hepar	
812430	57			Tulang, hepar	
942600	41			Pleura	<i>Invasive carcinoma mammar of no special type, grade 2</i>
923800	47	ER(-) PR(-) Her 2(-)	<i>Triple negative</i>	Hepar	<i>Adenocarcinoma musinosum mammae</i>
906659	48			Pleura	<i>Adenocarcinoma musinosum mammae</i>
897358	40			Tulang (costa)	<i>Invasive carcinoma mammae of no special type, high grade malignancy</i>
897678	61	ER (+) PR(-)) Her 2(-)	Luminal B	Pleura	<i>Invasive carcinoma mammae of no special type, moderate grade malignancy</i>
821268	51	ER(-) PR(-) Her 2(-)	<i>Triple negative</i>	Paru	<i>Invasive ductal carcinoma mammae, comedo type, well differentiated</i>
900268	40	ER(-) PR(-) Her 2(-)	<i>Triple negative</i>	Paru/pleura	<i>Proses malignancy sesuai dengan scirrhous carcinoma</i>
874569	44	ER(-) PR(+) Her 2(+)	<i>Luminal B</i>	Tulang	<i>Invasive breast carcinoma of no special type, moderate grade malignancy</i>